High Yield Corp Bond Ishares Iboxx $ ETF (HYG)
$82.17 0.04 (0.05%)
9:45 EDT HYG Stock Quote Delayed 30 Minutes
Previous Close $82.21
Market Cap 18.15B
PE Ratio -
Volume (Avg. Vol.) 869,131
Day's Range 82.05 - 82.22
52-Week Range 67.52 - 88.53
Dividend & Yield 4.46 (5.43%)
HYG Stock Predictions, Articles, and High Yield Corp Bond Ishares Iboxx $ ETF News
- From InvestorPlace
- From the Web
The most bought ETFs since the March market bottom feature exposure to a variety of asset classes and some surprises, too.
It's no secret the market has seen some wild gyrations, but understanding that movement can help an options trader make money.
Some investors are flocking to high-yield ETFs, but the perceived lowering of risk there may just be setting them up for failure.
Keep an eye on China's stock indexes and high-yield bond funds as the market awaits more trade deal updates from President Donald Trump.
I think we’re setting up for one massive sell-on-the-news situation. If you’re not positioned for that now, you may not have a better chance.
With HYG threatening to break down from a bearish pattern, yesterday’s decline could be an ominous warning for the junk bond sector.
High-yield bonds are sending the stock market a warning sign despite all-time highs from the S&P 500 and a new rate cut.
The HYG etf has largely trotted sideways over the past couple of years and increasingly is tracing out a concerning pattern that ultimately could result to plenty of downside.
Last Thursday’s breakout to the upside for the S&P 500 was for real. The index will rally up to the 3,000-level before this phase is over.
We spotlight 7 of the best high-yield ETFs in diverse categories to help find the right funds for your portfolio.
High-yield corporate debt is one of the riskier corners of the bond market, but for investors who want to embrace some risk, there are plenty of rewards.
As the current fixed-income environment confirms, high-yield bond funds are not perfect. Like any other asset class, there are risks with these bond funds.
High-yield bond prices have nowhere to go but down if they want to generate yields that are going to be high enough to compete with “risk-free” Treasuries.
While there are some headwinds that could cause trouble, things are looking good for a strong finish. This is what investors need to know.
We expect that if stocks start to soften up after Friday’s labor report that any correction will be preceded by a decline in high-yield bonds.
I continue to respect the year-to-date up-trend in stocks but heading into this new trading week there are two red flags I am watching.
Harvard went big on the High-Yield Corporate Bond ETF (HYG), but other high-yield bond ETFs are worth looking at. Here are the top three.
The SPDR Bloomberg Barclays High Yield Bond ETF (JNK) is smaller than rival HYG, but does the JNK have it where it counts?
iShares iBoxx $ High Yield Corporate Bond ETF (HYG) is one of the largest bond ETFs of any stripe. But is HYG right for you?
Analysts Offer Insights on Healthcare Companies: Evoke Pharma (NASDAQ: EVOK) and Summit Therapeutics (NASDAQ: SMMT)
From Analyst Ratings
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Evoke Pharma (EVOK – Research Report) and Summit Therapeutics (SMMT – Research Report) with bullish sentiments. Evoke Pharma (EVOK) H.C. Wainwright analyst Ram Selvaraju upgraded Evoke Pharma to Buy today and set a price target of $10.00.
Analysts Offer Insights on Healthcare Companies: ChemoCentryx (NASDAQ: CCXI), Y-Mabs Therapeutics (NASDAQ: YMAB) and Summit Therapeutics (NASDAQ: SMMT)
From Analyst Ratings
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ChemoCentryx (CCXI – Research Report), Y-Mabs Therapeutics (YMAB – Research Report) and Summit Therapeutics (SMMT – Research Report) with bullish sentiments. ChemoCentryx (CCXI) Canaccord Genuity analyst Michelle Gilson maintained a Buy rating on ChemoCentryx yesterday and set